Duloxetine reduces pain more than placebo in painful diabetic peripheral neuropathy, and the size of that benefit is modest. In a 2023 systematic review and meta-analysis of 7 randomized controlled trials in adults with painful diabetic peripheral neuropathy, duloxetine was more efficacious than placebo for pain improvement, with a mean difference of -0.89 (95% confidence interval -1.09 to -0.69; P <.00001) [1].
The limits sit in two places: whether you can tolerate it long enough for the benefit to matter, and whether the driver behind the nerve injury is still active while you take it.
What the pooled trial evidence supports
The same 2023 meta-analysis also found improvement on the Clinical Global Impression severity subscale, the Patient Global Impression of Improvement scale, and the European Quality of Life Instrument 5D version, all in patients with painful diabetic peripheral neuropathy [1].
On dosing, the authors concluded that when a 60 mg dose is insufficient, 120 mg of duloxetine may improve symptoms [1]. That is an evidence statement, not a self-escalation instruction. Dose decisions belong with the prescribing clinician, particularly alongside other medications or with liver, blood pressure or bleeding considerations.
What it does not do
Duloxetine acts on pain signaling. It does not reduce glycation damage, improve delivery through the vasa nervorum, or correct a nutritional deficit. Where one of those is the active driver, the medication can help with the sensation while the underlying problem continues.
Tolerability is where the evidence turns
In the pooled trial data, severe adverse events were rare. Nausea, somnolence, dizziness, fatigue, constipation and decreased appetite were common, and approximately 12.6% of patients discontinued because of those common symptoms [1].
A 2025 single-center study of 113 adults aged 25 to 65 with diabetic neuropathy, treated at a provincial hospital in Quetta, Pakistan, reported adverse effects in 32 patients (28.3%), most often nausea in 12 (10.6%), dizziness in 8 (7.1%) and somnolence in 7 (6.2%) [2]. Observational data cannot establish causation the way a randomized trial can, but it gives a sense of what tolerability looks like outside a trial protocol.
Why the driver still matters
Neuropathy is a category, not a diagnosis. Even when diabetes is clearly present, other contributors are frequently active at the same time, and they change what the rest of the plan should be.
- Glycation and AGEs, which continue to act on nerve tissue regardless of what a pain medication is doing.
- Functional B12 deficiency, which can be missed when a serum value in the normal range is treated as settled.
- Gluten-related nerve injury, which can occur even with a negative celiac panel.
- Medication effects, including agents that affect nutrient status and warrant monitoring.
The clinical work at Regenerve is aimed at that layer: restoring microvascular perfusion so oxygen reaches the nerve, reducing the metabolic pathways producing glycation damage, and supplying the substrates nerves need, all under physician evaluation. That is the layer a pain medication does not reach.
Testing that tells you whether the evidence applies to you
The trials above enrolled patients with painful diabetic peripheral neuropathy. Whether that describes your situation is a question the workup answers, not the diagnosis label on the chart.
Electrodiagnostic testing
EMG and nerve conduction studies, performed on site, characterize which fibers are involved and can separate a systemic neuropathy from a compression pattern. That matters most when symptoms suggest more than one mechanism at once.
Balance testing is diagnostic only
Videonystagmography, or VNG, measures inner-ear balance function. It clarifies whether a second system is contributing to unsteadiness. It is a test, not a treatment.
Small fiber involvement
Small fiber neuropathy can produce burning and sensory change that a single test will not always capture, which is one reason the evaluation focuses on the driver profile rather than on confirming the word neuropathy.
What sits alongside medication
None of this is framed as an alternative to duloxetine. Class 4 photobiomodulation and class 3B cold laser are used as part of neuropathy care, and whole-body infrared is also offered. Where gait and sensory feedback are affected, whole-body vibration may be part of the broader plan.
For how these fit together for foot-predominant symptoms, see diabetic peripheral neuropathy treatment in St. Louis.
Frequently asked questions
How much pain relief does duloxetine actually provide?
In a 2023 meta-analysis of 7 randomized controlled trials in adults with painful diabetic peripheral neuropathy, duloxetine beat placebo on pain improvement by a mean difference of -0.89 (95% CI -1.09 to -0.69; P <.00001) [1]. That is a real effect and a modest one, which is why it usually sits alongside driver-focused care rather than replacing it. See peripheral neuropathy treatments for the feet.
What side effects most often make people stop?
In the same pooled trial data, severe adverse events were rare, while nausea, somnolence, dizziness, fatigue, constipation and decreased appetite were common; about 12.6% of patients dropped out because of those common symptoms [1]. Tolerability, not efficacy, is usually the deciding factor. See small fiber neuropathy symptoms and testing.
If 60 mg is not enough, does going to 120 mg help?
The 2023 meta-analysis concluded that when a 60 mg dose is insufficient, 120 mg may improve symptoms in painful diabetic peripheral neuropathy [1]. That is a physician decision, and it depends on what else you take and on liver, blood pressure and bleeding risk. See why a negative celiac test does not close the question.
What if my neuropathy is not only diabetic?
Then the evidence base fits your situation less well, because these trials enrolled patients with painful diabetic peripheral neuropathy specifically. Nutritional, autoimmune, toxic and structural drivers can run alongside diabetes and change what the plan should prioritize. See why a normal B12 result can still miss a deficiency.
Decide with a map, not a trial and error
Whether duloxetine belongs in your plan is easier to answer once you know which driver is doing the most damage. The free five-question Nerve Damage Score at regenerve.com/assessment is where that conversation starts.
Sources
- Wu CS, Huang YJ, Ko YC, Lee CH, Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials, Systematic Reviews (BMC), 2023, doi:10.1186/s13643-023-02185-6, https://pmc.ncbi.nlm.nih.gov/articles/PMC10031998/.
- Osama M, Javaid M, Shahid B, Heema, Jamali AG, Anwar B, Mushtaq T, Efficacy of duloxetine in the management of diabetic neuropathy: a prospective observational cohort study, Cureus, 2025, doi:10.7759/cureus.82382, https://pmc.ncbi.nlm.nih.gov/articles/PMC12089739/.